v3.19.3
Note 1 - Organization and Basis of Presentation (Details Textual)
1 Months Ended
May 31, 2019
USD ($)
May 03, 2019
May 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Cash and Cash Equivalents, at Carrying Value, Ending Balance         $ 24,000 $ 1,887,000
Retained Earnings (Accumulated Deficit), Ending Balance         (44,417,000) $ (37,279,000)
Majority Investors [Member] | First Note to Fund the Company's Operations [Member]            
Proceeds from Notes Payable, Total       $ 2,000,000    
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]            
Proceeds from Notes Payable, Total $ 500,000   $ 500,000      
Majority Investors [Member] | Notes to Fund the Company's Operations [Member]            
Debt Instrument, Interest Rate, Stated Percentage 8.00%   8.00%      
Convertible Debt [Member]            
Notes Payable, Total         5,600,000  
Oxford Finance, LLC [Member]            
Loans Payable, Total         $ 3,000,000  
Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]            
Stockholders' Equity Note, Stock Split, Conversion Ratio   6        
Alliqua Biomedical, Inc. [Member]            
Business Acquisition, Exchange Ratio   0.0359